Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab and Milk Oral Immunotherapy for the Treatment of Patients With Cow's Milk Allergy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Milk hypersensitivity
- Focus Therapeutic Use
- 02 Oct 2023 Planned End Date changed from 1 May 2024 to 1 Nov 2026.
- 02 Oct 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Oct 2026.
- 16 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 May 2024.